Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
SEP-225289
DRUG
2 trials
Sponsors
Sumitomo Pharma America, Inc.
Conditions
Adult Attention Deficit Hyperactivity Disorder
Depressive Disorder, Major
Phase 2
A Safety, Efficacy and Tolerability Study of SEP-225289
Completed
NCT00584974
Sumitomo Pharma America, Inc.
Depressive Disorder, Major
Start: 2007-12-31
End: 2009-05-31
Updated: 2012-02-23
Adult Attention Deficit Hyperactivity Disorder
Completed
NCT01692782
Sumitomo Pharma America, Inc.
Adult Attention Deficit Hyperactivity Disorder
Start: 2012-12-31
End: 2013-12-31
Updated: 2015-01-12
Related Papers
Characterization of the Safety Profile of the Triple Monoamine Reuptake Inhibitor Dasotraline Based on Clinical Trial Data and Disproportionality Analyses of Four Related Pharmacological Classes Using Real-World Data from the FDA Adverse Event Reporting System.
2026-02-16
Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
Clinical Drug Investigation
2015-11-23
30 citations